Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (11 quarters reported)
$280M in Q4 2023 → $2.19B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Abivax Sa | 11.0% | Added 29% | 1,804,703 | $240M |
| Protagonist Therapeutics Inc | 5.4% | Trimmed 3.3% | 960,863 | $118M |
| Roivant Sciences Ltd | 5.1% | Trimmed 3.9% | 3,157,008 | $112M |
| SS State Str SPDR S&P 500 ETF T | 4.4% | Added 70% | 129,087 | $96.4M |
| Immunovant Inc | 4.1% | Trimmed 13% | 2,330,716 | $89.8M |
| Zai Lab Ltd | 2.9% | Added 136% | 3,369,034 | $64M |
| Agios Pharmaceuticals Inc | 2.2% | Added 816% | 1,288,053 | $47.8M |
| CP Crinetics Pharmaceuticals In | 2.1% | Added 7.3% | 1,222,080 | $45.7M |
| ES Ea Series Trust | 1.8% | Unchanged | 337,125 | $39.5M |
| Cytokinetics Inc | 1.8% | Trimmed 28% | 457,907 | $39M |
| Septerna Inc | 1.4% | Trimmed 14% | 940,747 | $31.5M |
| Anteris Technologies Global | 1.4% | Trimmed 17% | 3,145,096 | $31M |
| Editas Medicine Inc | 1.3% | New | 8,889,000 | $28.8M |
| Denali Therapeutics Inc | 1.2% | Trimmed 45% | 1,029,080 | $26.5M |
| Spyre Therapeutics Inc | 1.2% | Trimmed 16% | 283,982 | $25.2M |
| Vir Biotechnology Inc | 1.1% | Trimmed 10% | 2,456,677 | $25M |
| PP Praxis Precision Medicines I | 1.1% | Added 4850% | 74,253 | $24.9M |
| Insmed Inc | 1.1% | Added 546% | 228,520 | $24.4M |
| CT Celldex Therapeutics Inc New | 1.1% | Added 45% | 619,542 | $23.1M |
| Viking Therapeutics Inc | 1.0% | Added 152% | 574,038 | $22.4M |
| Taysha Gene Therapies Inc | 0.9% | Added 2.0% | 3,040,466 | $20.7M |
| Monopar Therapeutics Inc | 0.9% | Trimmed 18% | 217,595 | $20.1M |
| Ovid Therapeutics Inc | 0.9% | Added 63% | 7,417,479 | $20M |
| Enliven Therapeutics Inc | 0.9% | Added 18% | 387,718 | $19.7M |
| Enanta Pharmaceuticals Inc | 0.9% | Added 2518% | 1,344,510 | $19.6M |
| IT Ishares Tr Put | 0.9% | Added 127% | 62,500 | $18.8M |
| SS State Str SPDR S&P 500 ETF T Put | 0.9% | New | 25,000 | $18.7M |
| Nektar Therapeutics | 0.8% | Added 51% | 244,184 | $17M |
| IM Inspire Med Sys Inc | 0.8% | Trimmed 7.5% | 374,617 | $16.7M |
| Revolution Medicines Inc | 0.7% | Trimmed 35% | 87,509 | $16.4M |
| EL Establishment Labs Hldgs Inc | 0.7% | Trimmed 13% | 185,619 | $15.9M |
| PP Prothena Corp PLC | 0.7% | Trimmed 1.7% | 1,554,535 | $15.2M |
| Rhythm Pharmaceuticals Inc | 0.7% | Trimmed 36% | 136,158 | $15.1M |
| Inhibikase Therapeutics Inc | 0.7% | Added 12% | 7,387,205 | $15M |
| Uniqure Nv | 0.7% | Added 326% | 324,672 | $15M |
| Rallybio Corp | 0.7% | Added 4411% | 926,352 | $14.8M |
| Regeneron Pharmaceuticals | 0.6% | Added 83% | 22,208 | $13.8M |
| IS Inventiva Sa | 0.6% | Added 66% | 3,606,656 | $13.6M |
| Sutro Biopharma Inc | 0.6% | Trimmed 23% | 404,014 | $13.4M |
| Ionis Pharmaceuticals Inc | 0.6% | Added 3.7% | 166,286 | $13.2M |
| Bridgebio Pharma Inc | 0.6% | Added 87% | 176,689 | $13.2M |
| Sarepta Therapeutics Inc | 0.6% | Added 179% | 730,649 | $13.1M |
| Cytomx Therapeutics Inc. | 0.6% | Trimmed 1.3% | 3,365,118 | $12.6M |
| Vor Biopharma Inc | 0.6% | New | 680,626 | $12.5M |
| SS SPDR Series Trust | 0.6% | Unchanged | 135,585 | $12.4M |
| Equillium Inc | 0.6% | Added 0.9% | 3,758,569 | $12M |
| AN Adlai Nortye Ltd | 0.5% | Added 763% | 1,017,805 | $11.7M |
| Climb Bio Inc | 0.5% | Added 38% | 822,649 | $10.7M |
| SS SPDR Series Trust Put | 0.5% | Added 349% | 67,400 | $10.7M |
| Helix Acquisition Corp Iii | 0.5% | Unchanged | 1,000,000 | $10.6M |
| Zura Bio Ltd | 0.5% | Added 179% | 1,759,295 | $10.4M |
| Onkure Therapeutics Inc | 0.5% | Trimmed 8.1% | 2,238,684 | $10.2M |
| Maze Therapeutics Inc | 0.5% | Added 577% | 339,276 | $10.1M |
| Xenon Pharmaceuticals Inc | 0.5% | Trimmed 27% | 166,550 | $10.1M |
| TP Teva Pharmaceutical Inds Ltd | 0.4% | Added 3.5% | 277,848 | $9.41M |
| Urogen Pharma Ltd | 0.4% | Trimmed 36% | 252,395 | $9.29M |
| Faeth Therapeutics Inc | 0.4% | New | 361,010 | $9.03M |
| Amylyx Pharmaceuticals Inc | 0.4% | Trimmed 51% | 494,378 | $8.88M |
| Dbv Technologies S A | 0.4% | Trimmed 48% | 528,295 | $8.66M |
| Savara Inc | 0.4% | Trimmed 4.2% | 1,403,409 | $8.64M |
Showing top 60 of 277 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Abivax Sa | Added | +410,684 | +$54.7M | 11.0% |
| Terns Pharmaceuticals Inc | Exited | −914,699 | −$48.2M | — |
| Agios Pharmaceuticals Inc | Added | +1,147,381 | +$42.6M | 2.2% |
| SS State Str SPDR S&P 500 ETF T | Added | +53,147 | +$39.7M | 4.4% |
| Zai Lab Ltd | Added | +1,943,667 | +$36.9M | 2.9% |
| Beam Therapeutics Inc | Exited | −1,446,375 | −$34.5M | — |
| Editas Medicine Inc | New | +8,889,000 | +$28.8M | 1.3% |
| PP Praxis Precision Medicines I | Added | +72,753 | +$24.4M | 1.1% |
| Denali Therapeutics Inc | Trimmed | −842,375 | −$21.7M | 1.2% |
| Insmed Inc | Added | +193,128 | +$20.6M | 1.1% |
Showing the 10 largest of 289 changes.
quarter ended March 31, 2026 · filed May 18, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Avidity Biosciences Inc | Exited | −546,534 | −$39.4M | — |
| Denali Therapeutics Inc | Added | +1,819,339 | +$34.9M | 2.1% |
| Beam Therapeutics Inc | New | +1,446,375 | +$34.5M | 2.0% |
| CP Crinetics Pharmaceuticals In | Added | +829,963 | +$30.1M | 2.4% |
| Vir Biotechnology Inc | New | +2,744,714 | +$24.6M | 1.4% |
| Dbv Technologies S A | New | +1,012,866 | +$21.2M | 1.2% |
| IM Inspire Med Sys Inc | Added | +390,197 | +$20.1M | 1.2% |
| Terns Pharmaceuticals Inc | Added | +373,084 | +$19.7M | 2.8% |
| Rapt Therapeutics Inc | Exited | −509,679 | −$17.3M | — |
| SR Scholar Rock Hldg Corp | Added | +337,684 | +$16.6M | 1.2% |
Showing the 10 largest of 286 changes.
quarter ended December 31, 2025 · filed February 18, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Keros Therapeutics Inc | Trimmed | −5,370,413 | −$109M | — |
| Avidity Biosciences Inc | Added | +492,878 | +$35.6M | 2.9% |
| 89bio Inc | Exited | −2,113,153 | −$31.1M | — |
| SS SPDR S&P 500 ETF Tr | Exited | −45,500 | −$30.3M | — |
| Bioage Labs Inc | Trimmed | −1,744,513 | −$23.1M | 0.1% |
| Terns Pharmaceuticals Inc | Added | +531,615 | +$21.5M | 1.6% |
| CT Celldex Therapeutics Inc New | Added | +537,325 | +$14.6M | 1.3% |
| IS Inventiva Sa | New | +2,709,846 | +$12.6M | 0.9% |
| Arbutus Biopharma Corp | Added | +2,511,883 | +$12.1M | 1.9% |
| Fulcrum Therapeutics Inc | Added | +912,137 | +$10.3M | 1.0% |
Showing the 10 largest of 257 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Bridgebio Pharma Inc | Trimmed | −4,455,000 | −$440M | 0.4% |
| Bridgebio Pharma Inc | Trimmed | −1,980,000 | −$278M | 0.3% |
| Abivax Sa | Trimmed | −1,720,514 | −$146M | 10.8% |
| Immunovant Inc | Added | +1,706,687 | +$27.5M | 3.4% |
| SS SPDR S&P 500 ETF Tr | Added | +32,000 | +$21.3M | 3.4% |
| Roivant Sciences Ltd | Added | +1,406,704 | +$21.3M | 4.8% |
| PP Prothena Corp PLC | Trimmed | −1,905,911 | −$18.6M | 1.3% |
| 89bio Inc | Added | +1,237,170 | +$18.2M | 2.9% |
| Uniqure Nv | New | +200,000 | +$11.7M | 1.1% |
| Cg Oncology Inc | Trimmed | −274,299 | −$11M | 0.9% |
Showing the 10 largest of 236 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Keros Therapeutics Inc | Added | +3,902,803 | +$52.1M | 11.0% |
| SS SPDR S&P 500 ETF Tr | New | +40,500 | +$25M | 3.8% |
| PP Prothena Corp PLC | New | +3,375,009 | +$20.5M | 3.1% |
| Roivant Sciences Ltd | Trimmed | −1,542,607 | −$17.4M | 3.4% |
| SS SPDR S&P 500 ETF Tr | New | +22,684 | +$14M | 2.1% |
| Springworks Therapeutics Inc | Trimmed | −183,696 | −$8.63M | 0.2% |
| Rapt Therapeutics Inc | Exited | −5,970,768 | −$7.28M | — |
| Immunovant Inc | Trimmed | −433,800 | −$6.94M | 1.3% |
| Cytomx Therapeutics Inc | Added | +3,034,378 | +$6.89M | 1.1% |
| Abivax Sa | Added | +861,321 | +$6.59M | 3.6% |
Showing the 10 largest of 206 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Keros Therapeutics Inc | Added | +1,463,215 | +$14.9M | 2.8% |
| Bridgebio Pharma Inc | Trimmed | −339,222 | −$11.7M | 2.2% |
| Ascendis Pharma A/s | Trimmed | −70,000 | −$10.9M | — |
| Mineralys Therapeutics Inc | Trimmed | −578,116 | −$9.18M | 0.8% |
| Springworks Therapeutics Inc | New | +207,778 | +$9.17M | 1.7% |
| IT Ishares Tr | New | +103,337 | +$8.55M | 1.6% |
| Janux Therapeutics Inc | New | +264,900 | +$7.15M | 1.3% |
| EG Endeavor Group Hldgs Inc | Exited | −210,729 | −$6.59M | — |
| IT Intra-cellular Therapies Inc | New | +48,044 | +$6.34M | 1.2% |
| Rapt Therapeutics Inc | Added | +4,796,455 | +$5.85M | 1.4% |
Showing the 10 largest of 224 changes.
quarter ended December 31, 2024 · filed February 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Royalty Pharma PLC | Trimmed | −1,046,703 | −$26.7M | 0.3% |
| Cytokinetics Inc | Trimmed | −496,973 | −$23.4M | 3.9% |
| Bridgebio Pharma Inc | Trimmed | −769,613 | −$21.1M | 3.7% |
| Inhibikase Therapeutics Inc | New | +5,103,005 | +$16.6M | 3.3% |
| Zai Lab Ltd | Added | +513,383 | +$13.4M | 5.5% |
| Ascendis Pharma A/s | Trimmed | −90,000 | −$12.4M | 2.0% |
| SS SPDR Ser Tr | Added | +110,000 | +$10.1M | 2.4% |
| Immunovant Inc | Trimmed | −344,229 | −$8.53M | 3.9% |
| Kezar Life Sciences Inc | Trimmed | −1,190,869 | −$8M | 0.2% |
| Abivax Sa | Added | +991,781 | +$7.26M | 2.2% |
Showing the 10 largest of 292 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Protagonist Therapeutics Inc | Trimmed | −622,637 | −$28M | 7.2% |
| Immunovant Inc | Added | +655,164 | +$18.7M | 5.2% |
| Ascendis Pharma A/s | Added | +110,139 | +$16.4M | 3.9% |
| Zura Bio Ltd | New | +3,770,649 | +$15.3M | 2.5% |
| Insmed Inc | Exited | −200,800 | −$13.5M | — |
| Roivant Sciences Ltd | Trimmed | −1,124,559 | −$13M | 5.7% |
| Zai Lab Ltd | Added | +510,454 | +$12.3M | 2.1% |
| Edgewise Therapeutics Inc | Trimmed | −418,430 | −$11.2M | 0.1% |
| Aa Mission Acquisition Corp | New | +1,010,199 | +$10.1M | 1.6% |
| Insmed Inc | Exited | −150,000 | −$10.1M | — |
Showing the 10 largest of 345 changes.
Loading...
